mtmdphd Profile Banner
Mike Thompson, MD, PhD, FASCO Profile
Mike Thompson, MD, PhD, FASCO

@mtmdphd

Followers
23K
Following
141K
Media
17K
Statuses
144K

#MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau

Milwaukee, WI
Joined September 2010
Don't wanna be here? Send us removal request.
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
3 months
Myeloma / Plasma Cell Dyscrasia ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd.- Update: 6/3/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani
Tweet media one
1
6
23
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
11 hours
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
Tweet media one
0
0
1
@grok
Grok
@grok
8 days
Join millions who have switched to Grok.
221
457
3K
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
11 hours
Quantifying the Value of Molecular Tumor Board: Discordance Rec Rate & Drug Cost Avoidance [Oct 20, 2022] @mkwalters305 et al. @JCOPO_ASCO #PrecisionMedicine #hpeonc Table 2
Tweet media one
0
0
2
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
11 hours
Quantifying the Value of Molecular Tumor Board: Discordance Rec Rate & Drug Cost Avoidance [Oct 20, 2022] @mkwalters305 et al. @JCOPO_ASCO #PrecisionMedicine #hpeonc Table 1. Recommendation Discordance Definition
Tweet media one
1
0
3
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
11 hours
Quantifying the Value of Molecular Tumor Board: Discordance Recommendation Rate & Drug Cost Avoidance [10/20/22] @mkwalters305 @JimW9200 @antonyruggeri @mullane_michael Hunt, Wilson, Ramczyk, @mtmdphd @JCOPO_ASCO #PrecisionMedicine #hpeonc @Aurora_Cancer
Tweet media one
1
1
3
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
11 hours
A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial [Aug 14, 2025] Zane et al. @CCR_AACR .#PrecisionMedicine @theNCI
Tweet media one
0
0
2
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
11 hours
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) [Oct 13, 2020] Flaherty et al. @JCO_ASCO.#EAonc #PrecisionMedicine.
Tweet card summary image
ascopubs.org
PURPOSETherapeutically actionable molecular alterations are widely distributed across cancer types. The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial was designed...
0
1
5
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
16 hours
#mmMRD #mmsm #ImmunoOnc.
@Myeloma_Doc
Robert Z. Orlowski
@Myeloma_Doc
2 days
#Myeloma Paper of the Day: Immune-MRD status informs tumor-MRD outcome prognostication in myeloma pts on Len maintenance; T cell profiles enriched w/ activated cytotoxic effectors predict early relapse & quiescent/naïve T-cells predicting remission: #mmsm
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
0
1
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
2 days
#melsm #ImmunoOnc.
@PatrickHwuMD
Dr. Patrick Hwu
@PatrickHwuMD
2 days
Congrats to @LabSmalley and team on their new @jitcancer paper! A 3-drug #immunotherapy combo may overcome resistance in #melanoma, restoring immune response & shrinking tumors in preclinical models without added side effects. Read more below:
0
0
0
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
2 days
I’m reminded of a book from (I think) elementary school
Tweet media one
1
0
1
@barstoolsports
Barstool Sports
@barstoolsports
6 days
RT @PardonMyTake: Tuesday night max woke Big Cat up with a flashlight at 2am because he thought we were going to get sued. @forthepeople ht….
0
22
0
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
3 days
RT @Larvol: 📣 𝕏 Post of the Day (August 24, 2025). Dr. Yüksel Ürün, MD (@DrYukselUrun), notes updates on KRAS-targeted cancer vaccine (ELI-….
0
10
0
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
3 days
#melsm @SWOGonc #ctsm.
@NatureMedicine
Nature Medicine
@NatureMedicine
3 days
RESEARCH. In cohort B of the phase 2 SWOG S1512 trial, pembrolizumab monotherapy in patients with unresectable desmoplastic melanoma elicited a complete response rate of 37% & an objective response rate of 89%, supporting a new treatment option for this tumor type.
0
0
0
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
4 days
RT @doximity: We’re excited to welcome Pathway to the Doximity family!. Pathway’s physician-led team has built one of the largest structure….
0
2
0
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
5 days
#mmsm #CARTcell #caxtx.
@corynnkasap
Corynn Kasap
@corynnkasap
5 days
Excited to share our new manuscript, now published in Blood! BCMA #CART show impressive responses for #myeloma, but pts with high-risk cytogenetics relapse more quickly and are in urgent need of new therapies. Thread👇 (1/10)
Tweet media one
0
0
2
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
5 days
RT @TempusAI: We’re excited to announce our acquisition of @paige_ai, an AI company specializing in digital pathology. This acquisition al….
0
23
0
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
5 days
RT @TempusAI: The recording of our recent webinar is now available. Dr. Ezra Cohen, was joined by Drs. Sara Tolaney, Nataliya Uboha and Cyn….
0
8
0
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
6 days
RT @ASCO: Early-career oncologists: Last call to apply for YIA and GO YIA funding! Don’t miss this deadline. Apply today: .
0
10
0
@talkspace
talkspace
@talkspace
5 months
If you’re hunting for good news here’s something: Talkspace therapy is covered by most insurance plans and the average copay is only $15 (but most covered members pay $0).
33
98
808
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
7 days
RT @FrancescoMaura4: Excited to share our new paper, out today on @NatureGenet where we use 421 #WGS to reconstruct the evolutionary histo….
0
35
0
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
7 days
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dex (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
Tweet media one
Tweet media two
0
3
25
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
7 days
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx
Tweet media one
Tweet media two
Tweet media three
1
0
1
@mtmdphd
Mike Thompson, MD, PhD, FASCO
@mtmdphd
7 days
MT @eaonc Inaugural [2018] meeting of the ECOG-ACRIN Big Data Working Group, in Fort Lauderdale #bigdata
Tweet media one
Tweet media two
2
1
7